RedHill Biopharma (RDHL) Long-Term Debt Issuances (2020)

RedHill Biopharma's (RDHL) quarterly Long-Term Debt Issuances came in at -$784000.0 in Q3 2020, down 56.8% on a QoQ basis from -$500000.0 in Q2 2020.

RedHill Biopharma (RDHL) Long-Term Debt Issuances (2020) Analysis & Trends

RedHill Biopharma (RDHL) has 1 years of Long-Term Debt Issuances data on file, last reported at -$784000.0 in Q3 2020.

On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to -$784000.0 in Q3 2020; TTM through Dec 2020 was $78.1 million, a N/A change from a year earlier, with the FY2020 full-year figure at $78.1 million, changed N/A from the prior year.
Long-Term Debt Issuances for Q3 2020 stood at -$784000.0, down from -$500000.0 in the prior quarter.
Over the last five years, Long-Term Debt Issuances for RDHL reached as high as $79.3 million in Q1 2020 and fell as low as -$784000.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Haleon	88.07 Bn	86.20 Bn	-	-
2	Teva Pharmaceutical Industries	35.75 Bn	32.01 Bn	1.97 Bn	-
3	Zoetis	31.84 Bn	29.90 Bn	1.62 Bn	-
4	Takeda Pharmaceutical	27.18 Bn	23.12 Bn	4.39 Bn	3.64 Bn
5	United Therapeutics	23.09 Bn	20.93 Bn	648.10 Mn	-
6	RedHill Biopharma	21.32 Bn	21.32 Bn	-	-
7	Viatris	19.96 Bn	18.16 Bn	1.16 Bn	-
8	Neurocrine Biosciences	17.66 Bn	16.34 Bn	800.70 Mn	-
9	Elanco Animal Health	12.44 Bn	12.02 Bn	785.00 Mn	-
10	Vireo Growth	10.53 Bn	10.38 Bn	59.30 Mn	4.50 Mn

Download Data